Os desfechos da terapia com hormônio do crescimento para pacientes com síndrome de Prader-Willi em parâmetros da apneia obstrutiva do sono: uma revisão sistemática

Abstract

Introduction: Prader-Willi Syndrome (PWS) is a genetic condition that has growth hormone (GH) therapy as one of its main treatments. Such management is controversial regarding its effects on the respiratory parameters of these patients, especially in cases of Obstructive Sleep Apnea (OSA), making an analysis of this relationship necessary. Objective: To identify and summarize the effects of GH therapy for PWS patients on their OSA parameters. Methods: A systematic review of literature registered on the PROSPERO platform (CRD42023404250) was carried out, searching the Pubmed, Scopus and Web of Science databases. Results: Of 2,668 initial articles, three randomized controlled trials were considered eligible. None of the three studies demonstrated statistically significant changes in OSA parameters following GH administration. Conclusion: GH therapy is safe for patients with PWS in terms of OSA parameters.